期刊文献+

尘螨肠道微生物蛋白Hypothetical protein CE2118的表达及纯化

Expression and purification of intestinal microflora protein hypothetical CE2188in dust mites
下载PDF
导出
摘要 目的研究尘螨肠道微生物蛋白Hypothetical protein CE2118的表达和纯化,为研究其在尘螨疫苗免疫治疗中的作用奠定基础。方法采用生物信息学方法,根据GenBank中Hypothetical protein CE2118蛋白的基因序列,将其中稀有密码子改造为大肠杆菌常用密码子并进行二级结构优化,合成Hypothetical protein CE2118基因,构建原核表达载体pGEX6P-1-hypothetical protein CE2118并经酶切鉴定,在大肠埃希菌Rosetta(DE3)中用异丙基-β-D-硫代半乳糖苷(IPTG)诱导表达,重组产物采用GST亲和层析纯化柱纯化。结果经密码子改造和二级结构优化后Hypothetical protein CE2118基因长度为588bp,其编码蛋白理论分子量为21kDa。重组表达载体经酶切鉴定与理论推测结果相符,该基因经IPTG诱导在大肠埃希菌Rosetta(DE3)中得到高效的可溶性表达,纯化后的重组蛋白分子量约为21kDa,其单一蛋白纯度达95%以上。结论本研究成功构建了Hypothetical protein CE2118基因的pGEX6P-1原核重组质粒,获得的可溶性重组蛋白为进一步研究肠道微生物蛋白Hypothetical protein CE2118在尘螨疫苗免疫治中的作用机理奠定基础。 To express and purify intestinal microflora protein hypothetical CE2188 in dust mites, the gene order of hypo- thetical CE2118 was obtained from the GenBank, the rare codon in the gene was changed to the commonly used codon of Esche- richia coli (E. coli), and the secondary structure was optimized by means of bioinformatics. Then the DNA sequence was syn- thesized and its prokaryotic expression vector pGEX 6P-l-hypothetical protein CE2118 was constructed. The vector was guided into E. coli Rosetta (DE3) and induced by IPTG. Finally, the recombine protein was purified by means of GST affinity col- umn. The gene length of the reformed and optimized hypothetical CE2188 was 588 bp and the theoretic molecular mass of the coding protein was about 21 kDa. The enzyme identification of the recombinant vector was agreed with the theoretic value. Sol- uble hypothetical protein CE2118 could he expressed efficiently in E. coli Rosetta (DEa) by IPTG. Molecular mass of purified recombine protein was about 21 kDa. The prokaryotic expression vector pGEX 6P-l-hypothetical protein CE2118 was construc- ted successfully in our research. Efficient expression and soluble hypothetical protein CE2118 could be used to investigate the role of hypothetical protein CE2118 in dust mite vaccine immunotherapy.
出处 《中国人兽共患病学报》 CAS CSCD 北大核心 2014年第9期879-883,共5页 Chinese Journal of Zoonoses
基金 国家自然科学基金(No.31328014 81300028) 广东省高等学校国际暨港澳台科技合作创新平台项目(No.2012gjhz0009) 深圳市科技计划基础研究重点项目(No.JCYJ20120613100657482)~~
关键词 尘螨 肠道微生物 Hypothetical PROTEIN CE2118蛋白 dust mite intestinal microflora hypothetical protein CE2118
  • 相关文献

参考文献16

  • 1Portnoy J,Miller JD,Williams PB,et al.Environmental assess ment and exposure control of dust mites:a practice parameter[J].Ann Allergy Asthma Immunol,2013,111(6):465-507.DOI:10.1016/j.anai.2013.09.018.
  • 2Fujita H,Meyer N,Akdis M,et al.Mechanisms of immune tolerance to allergens[J].Chem Immunol Allergy,2012,96:3038.DOI:10.1159/000331868.
  • 3Refaat M,Ashour ZA,Farres MN,et al.Effect of tonsillectomy on the efficacy of house dust mitesublingual immunotherapy[J].Allergol Immunopathol (Madr),2014,pii:S0301-0546(13)00279-6.DOI:10.1016/j.aller.2013.09.007.
  • 4Vrtala S,Huber H,Thomas WR.Recombinant house dust mite allergens[J].Methods,2014,66(1):67-74.DOI:10.1016/j.ymeth.2013.07.034.
  • 5李国平,刘志刚,钟南山.支气管哮喘特异性免疫治疗与变应原疫苗的研究进展[J].国外医学(呼吸系统分册),2004,24(1):34-37. 被引量:19
  • 6Yu HQ,Li XH,Liu ZG,et al.Sublingual immunotherapy effi cacy of Dermatophagoides farinae vaccine in a murine asthma model[J].Int Arch Allergy Immunol,2010,152 (1):41 48.DOI:10.1159/000260082.
  • 7Casale TB,Stokes JR.Future forms of immunotherapy[J].JAllergy Clin Immunol,2011,127(1):8-15; quiz 16-7.DOI:10.1016/j.jaci.2010.10.034.
  • 8Jacquet A.Innate immune responses in house dust mite allergy[J].ISRN Allergy,2013,2013:735031.DOI:10.1155/2013/ 735031.
  • 9Kamada N,Seo SU,Chen GY,et al.Role of the gut microbiota in immunity and inflammatory disease[J].Nat Rev Immunol,2013,13(5):321 335.DOI:10.1038/nri3430.
  • 10Hill DA,Siracusa MC,Abt MC,et al.Commensal bacteria de rived signals regulate basophil hematopoiesis and allergic inflam mation[J].Natu Med,2012,18(4):538-546.DOI:10.1038/nm.2657.

二级参考文献21

  • 1Campbell D, DeKruyff RH, Umetsu DT.Allergen imnaunotherapy : novel approaches in the management of allergic diseases and ast hma. Clin lmmunol, 2000,97 : 193-202.
  • 2Bousquet J ,Lockey RF, Mailing HJ . Allergen immunotherapy:therapcuuc vaccines for allergic diseases. Allergy, 1998.53 ( 44 suppl) : 1-42.
  • 3Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Imnmnol. 1997.15:821-850.
  • 4Donovan CE, Finn PW. Immune mechanisms of childhood asthma. Thorax, 1999,54:938-946.
  • 5Korematsu S. Tanaka Y, Hosoi S, et al. C8/119S mutation of major mite allergen Derf-2 leads to degenerate secondary structure and molecular polymerization and induces potent and exclusive Thl cell differentiation. J Immunol, 2000, 165: 2895-2902.
  • 6Wierenga EA, Snoek M, de Groot C, et al. Evidence for compartmentalization of functional subsets of CD2 + T lymphocytes in atopic patienls. J Immunol, 1990, 114: 4651-4656.
  • 7Stirling RG, Chung KF. Future treatments of allergic diseases and asthma. Br Med Bull,2000,56:1037-1053.
  • 8Adkinson NF Jr, Eggleston PA ,Eney D,et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med, 1997,336 : 324-331.
  • 9Mareotte GV, Braun CM, Norman PS, et al. Effects of pcptide therapy on ex vivo T-cell responses. J Allergy Clin Immunol.1998,101(4 Pt 1):506-513.
  • 10Giannarini L, Maggi E. Decrease of allergen-specific T-cell response induced by local nasal immunotherapy. Clin Exp Allergy, 1998,28: 404-412.

共引文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部